Do HBV DNA-negative HBsAg-positive patients with compensated hepatitis B cirrhosis need antiviral therapy?
10.3969/j.issn.1001-5256.2023.01.006
- VernacularTitle:HBV DNA阴性、HBsAg阳性的乙型肝炎肝硬化代偿期患者需要抗病毒治疗吗？
- Author:
Li SU
1
,
2
;
Jinghang XU
1
;
Yaomin LIU
2
;
Guomin ZHANG
2
;
Yuting GUO
3
;
Guiqiang WANG
1
Author Information
1. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
2. Department of Infectious Diseases, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, China
3. First Department of Hepatology, The Third People's Hospital of Linfen City, Linfen, Shanxi 041000, China
- Publication Type:Academic Contention
- Keywords:
Hepatitis B virus;
Liver Cirrhosis;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(1):37-42
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a common cause of liver disease in China, and with the continuous progress in the research on antiviral therapy for chronic hepatitis B, the indications for antiviral therapy are constantly expanding. However, there are still controversies over the indications for antiviral therapy in patients with chronic hepatitis B (CHB), especially those with negative HBV. By analyzing the limitations of HBV DNA detection, the risk of HBV reactivation in HBV-negative CHB patients, the risk of disease progression in the DNA-negative population with compensated hepatitis B cirrhosis, antiviral response, and the economic benefits of antiviral therapy, this article proposes the necessity of antiviral therapy for HBV-negative HBsAg-positive patients with compensated hepatitis B cirrhosis.
